Powder Delivery TRIZ Cases

Stabilizing oligonucleotides in lipid nanoparticles protect RNA from exonuclease degradation and raise intracellular RNA and protein levels.

A eutectic of cyclobenzaprine HCl or amitriptyline HCl with mannitol improves API stability and supports faster sublingual or oral absorption.

Alkane-based rifabutin purification removes particle-forming impurities, enabling IV formulations that meet pharmacopeial limits.

CXCR4-targeted lipid nanoparticles improve CRISPR delivery to CD4+ T cells and myeloid cells while reducing immunogenicity and toxicity.

Hybrid polymer-phospholipid nanoassemblies protect aminoacidic drugs from degradation while improving targeting and intracellular delivery.

Acidic buffer and solvent ratio control keep albuvirtide stable during lyophilization and storage while reducing impurity formation.

Controlled olive cell culture in staged bioreactors yields a dried powder with consistent polyphenol levels and lower contamination risk.

A 5-40 mg oral esketamine regimen over at least 28 days balances symptom relief with lower mutagenicity risk in neuropsychiatric care.

Nanocapsulated silver nanoparticles and herbal extracts broaden pathogen coverage while enabling slow release, targeted delivery, and fewer applications.

A porous polymer shell keeps single cells and biomolecules contained while reagents diffuse in, enabling reliable multi-assay single-cell analysis.

A dihydrochloride dihydrate crystal form keeps trilaciclib soluble and stable in concentrated IV solution, preventing deposition in blood.

Novel spiropyrrolidine compounds inhibit coronavirus 3CLpro, blocking replication and supporting treatment to reduce severe infection outcomes.

A two-phase gamma-hydroxybutyrate formulation balances rapid and delayed dissolution to match twice-nightly exposure in one nighttime dose.

Precise polymer-oligonucleotide miktoarm conjugates improve uptake and nuclease resistance without toxic transfection carriers.

Excipient-dominant spray-dried particles stabilize aerosol properties across APIs, cutting dry powder inhaler formulation iterations, time, and cost.

PEOZ-lipid nanoparticles replace PEG coatings to preserve LNP stability while reducing IgM and IgG responses during repeated delivery.

Mist exposure to an aqueous plasticizer lets lyophilized silk fibroin powder form flexible, high-crystallinity solids at lower temperatures.

MnO2 nanoconstructs cross brain tumor barriers, release O2 in hypoxic tumors, and enable MRI tracking to improve radiotherapy response.

Surface-bound endogenous peptides let biodegradable microparticles absorb into dolphin tear film, enabling less invasive corneal drug delivery.

Direct lung delivery of kinase inhibitors in a dry powder inhaler helps treat IPF while reducing oral side effects and dosing inconsistency.

Electrostatic poly(I:C)-polyalkyleneimine particles improve formulation stability, homogeneity, and reproducible cancer delivery.

Standardized valerian extract balances valerenic acid yield and extraction control to improve sleep quality, duration, and disturbances.

An ion-exchange resin binds the active agent to enable rapid gastric release while resisting extraction in water or alcohol to deter abuse.

Automatic capsule piercing and vortex dispersion improve inhaled dose consistency and support both positive and negative pressure delivery.

Replacing PEG with polysarcosine in vitamin E derivatives improves water solubility while avoiding immunogenicity and toxicity.

Biotinylated PEG lipids and streptavidin-tagged antibodies enable stable, specific LNP-protein linkage without harsh chemistry or residual reagents.

Surface-modified silica captures bile acids without water-absorption swelling, avoiding resin odor and improving oral tolerability.

Surfactant micelles make lipophilic cannabinoids water-soluble, enabling stable gels and patches for sustained transdermal dosing over 72 hours.

Using R(+) budesonide with bronchodilators in one inhaled composition improves airway treatment while reducing side effects and dosing burden.

Bioorthogonal click chemistry creates a stable nucleic acid scaffold that preserves cargo activity, improves reproducibility, and limits off-target effects.

Spray-dried enteric tablets protect alkaline phosphatase through the stomach, then solubilize by pH in the intestines for targeted oral delivery.

Co-precipitated zinc zoledronate particles boost humoral and cellular immunity where aluminum adjuvants fall short on Th1 response.

A degradable mineral coating adsorbs biologic agents for localized sustained release, preserving protein activity and reducing injection frequency.

Compaction followed by milling improves protein powder flowability, bulk density, and wettability while avoiding heat denaturation and additives.

Olive polyphenols and Lactobacillus reuteri are combined to rebalance nicotine-related oral dysbiosis and reduce inflammation, halitosis, and dry mouth.

Isolated CFTR-containing porosomes restore airway secretory function and improve mucin and chloride secretion while limiting side effects.

N-acetyl amino acid excipients lower viscosity in concentrated therapeutic protein formulations, easing manufacturing and subcutaneous injection.

Biotin-streptavidin linkage gives lipid nanoparticles stable, specific antibody attachment for precise RNA delivery to target cells and tissues.

An adapter holds capped dispensing containers in a planetary mixer to support uniform API mixing while reducing contamination, heat, and air entrapment.

Ionizing ibuprofen or naproxen with alkali metal salts stabilizes aqueous softgel fills with acetaminophen while keeping capsule size practical.

A multilayer blister uses aluminum, polyamide, and thermoplastic layers to protect lyophilized tablets from moisture, light, and freezing damage.

A Mif1-chaperone cargo module helps recombinant contractile injection structures deliver proteins, peptides, drugs, or markers into eukaryotic cells.

Small SR-BI-targeted micellar HDL nanoparticles improve paclitaxel solubility and cancer-cell uptake while reducing off-target toxicity.

SR-BI-targeted HDL-mimetic micelles improve chemotherapeutic solubility and release drugs inside cancer cells to reduce healthy-tissue toxicity.

Specific RXRB-targeting molecules bind tumor-associated macrophages to reduce immunosuppression and shift TAMs toward an anti-tumor M1 state.

A pH-responsive diblock copolymer improves tumor boundary imaging by activating in acidic tissue and clearing rapidly from normal tissue.

Freeze-dried LSD orally disintegrating tablets improve stability and content uniformity while enabling rapid release and easier dosing.

Using acid-substituted cyclodextrins as counterions at low molar ratios improves drug solubility while lowering osmolality and tissue irritation.

Constrained peptides such as CSPGAKVRC selectively bind CD206 on M2 tumor macrophages, improving imaging, drug delivery, and tumor control.